DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Trastuzumab emtansine is an investigational drug.
There have been 70 clinical trials for Trastuzumab emtansine. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Breast Neoplasms, Stomach Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dana-Farber Cancer Institute.
There are thirty-three US patents protecting this investigational drug and six hundred and eighty-eight international patents.
Recent Clinical Trials for Trastuzumab emtansine
|A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone||xuexin he||Phase 2|
|Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC||AC Camargo Cancer Center||Phase 2|
|DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer||AstraZeneca UK Limited||Phase 1|
Top disease conditions for Trastuzumab emtansine
Top clinical trial sponsors for Trastuzumab emtansine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Trastuzumab emtansine||Start Trial||Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds||Array BioPharma Inc. (Boulder, CO)||Start Trial|
|Trastuzumab emtansine||Start Trial||Methods for the treatment of HER2 amplified cancer||Pharmacyclics LLC (Sunnyvale, CA)||Start Trial|
|Trastuzumab emtansine||Start Trial||Encapsulated agents and methods of making and using thereof||University of Georgia Research Foundation, Inc. (Athens, GA)||Start Trial|
|Trastuzumab emtansine||Start Trial||Binding molecules specific for HER3 and uses thereof||MEDIMMUNE, LLC (Gaithersburg, MD)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Trastuzumab emtansine||Argentina||074052||2028-10-22||Start Trial|
|Trastuzumab emtansine||Australia||2009308465||2028-10-22||Start Trial|
|Trastuzumab emtansine||Australia||2015200511||2028-10-22||Start Trial|
|Trastuzumab emtansine||Australia||2017268517||2028-10-22||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|